Australian Clinical Labs Ltd
Australian Clinical Labs Limited provides pathology diagnostic services in Australia. The company offers range of services, including molecular cancer, harmony NIPT, genetic carrier screening and other antenatal, cardiac, and commercial drug and alcohol testing services; chemical pathology, haematology, histopathology and cytopathology, serology and microbiology, allergy and immunology, and veter… Read more
Australian Clinical Labs Ltd - Asset Resilience Ratio
Australian Clinical Labs Ltd (ACL) has an Asset Resilience Ratio of 4.11% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2025)
This chart shows how Australian Clinical Labs Ltd's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Australian Clinical Labs Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$22.43 Million | 3.99% |
| Short-term Investments | AU$703.00K | 0.12% |
| Total Liquid Assets | AU$23.14 Million | 4.11% |
Asset Resilience Insights
- Limited Liquidity: Australian Clinical Labs Ltd maintains only 4.11% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Australian Clinical Labs Ltd Industry Peers by Asset Resilience Ratio
Compare Australian Clinical Labs Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
ADCNF
OTCGREY:ADCNF |
Diagnostics & Research | 1.12% |
|
Berry Genomics Co Ltd
SHE:000710 |
Diagnostics & Research | 0.45% |
|
NSN Co. Ltd
KQ:031860 |
Diagnostics & Research | 1.72% |
|
JOONGANG DNM Co.Ltd
KQ:051980 |
Diagnostics & Research | 27.26% |
|
GeneMatrix Inc
KQ:109820 |
Diagnostics & Research | 41.52% |
|
Genoray Co. Ltd
KQ:122310 |
Diagnostics & Research | 0.03% |
|
Green Cross Lab Cell Corporation
KQ:144510 |
Diagnostics & Research | 0.18% |
|
Optipharm.CO.LTD
KQ:153710 |
Diagnostics & Research | 20.73% |
Annual Asset Resilience Ratio for Australian Clinical Labs Ltd (2016–2025)
The table below shows the annual Asset Resilience Ratio data for Australian Clinical Labs Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-06-30 | 3.85% | AU$22.12 Million | AU$574.84 Million | 0.00pp |
| 2024-12-31 | 3.85% | AU$22.12 Million | AU$574.84 Million | -0.68pp |
| 2024-06-30 | 4.53% | AU$26.84 Million | AU$593.06 Million | 0.00pp |
| 2023-12-31 | 4.53% | AU$26.84 Million | AU$593.06 Million | +0.97pp |
| 2023-06-30 | 3.56% | AU$20.59 Million | AU$578.91 Million | 0.00pp |
| 2022-12-31 | 3.56% | AU$20.59 Million | AU$578.91 Million | +3.38pp |
| 2022-06-30 | 0.18% | AU$1.13 Million | AU$628.04 Million | -4.20pp |
| 2021-12-31 | 4.38% | AU$27.51 Million | AU$628.04 Million | +4.16pp |
| 2021-06-30 | 0.22% | AU$1.05 Million | AU$474.70 Million | -7.42pp |
| 2020-12-31 | 7.64% | AU$36.28 Million | AU$474.70 Million | +7.52pp |
| 2020-06-30 | 0.12% | AU$435.00K | AU$366.05 Million | -9.52pp |
| 2019-12-31 | 9.64% | AU$35.28 Million | AU$366.05 Million | +8.99pp |
| 2019-06-30 | 0.65% | AU$1.00 Million | AU$153.61 Million | -2.69pp |
| 2018-12-31 | 3.34% | AU$5.13 Million | AU$153.61 Million | +0.89pp |
| 2018-06-30 | 2.45% | AU$2.91 Million | AU$119.06 Million | -5.77pp |
| 2017-12-31 | 8.22% | AU$9.78 Million | AU$119.06 Million | +7.97pp |
| 2017-06-30 | 0.25% | AU$301.00K | AU$120.89 Million | -5.82pp |
| 2016-12-31 | 6.07% | AU$7.34 Million | AU$120.89 Million | -- |